인사이트
Insights From Our Experts
Articles
CHALLENGING TRADITION: The argument for integrated commercialization to improve operational agility
Today’s economics simply do not support building commercial capabilities from scratch, only to dismantle that infrastructure until the next need arrives. Manufacturers will spend approximately $200 million of commercialization costs over three years leading up to the…
BLOG: Medication Adherence Opportunities and Challenges
Posted by
Dr. Richard Stefanacci on 8월 20, 20218/20/21
“Drugs don’t work in patients who don’t take them.” − Former U.S. Surgeon General C. Everett Coop While it seems obvious, the amount of attention given to adherence is extremely low, especially in comparison to the high costs associated with non-adherence.…
Realign Access Strategies to Overcome Challenges of Co-pay Assistance and Cost Sharing Trends
Kevin O’Meara, EVERSANA’s Vice President of Patient Services Solutions, joined Peter Avalos, National Reimbursement Director at Daiichi Sankyo, Inc., to discuss the current challenges impeding patient access and how to best optimize your co-pay programs using customized solutions and digital innovations.
American Medical Association Discusses New CPT Codes to Identify Digital Health Services
In our last update, we discussed the proposed rule that the Centers for Medicare and Medicaid Services (CMS) issued regarding the addition of certain Current Procedural Terminology (CPT®) codes to identify remote therapeutic monitoring (RTM) in…
CMS Releases Remote Therapeutic Monitoring Codes for 2022
The Centers for Medicare and Medicaid Services (CMS) released the proposed Medicare physician fee schedule regulation for 2022, which includes an analysis and payment calculations for the new Remote Therapeutic Monitoring (RTM) CPT codes issued by…
BLOG: ‘Bundling’ Payments to Assure Appropriate Rx Use
Posted by
Dr. Richard Stefanacci on 8월 6, 20218/6/21
In Medicare’s drive to improve outcomes of the fee-for-service (FFS) payment model, this model is being replaced with value-based care. The delivery of value-based care is not supported by FFS payments, which incentivize the volume of…
Competitive Benchmarking In Trade – Answering The Who, What, Why and When
Last month our colleague Derek Cothran addressed the importance of using secondary research to benchmark your Patient Support Program (PSP) against obvious and not-so-obvious competitors. We’d like to continue a discussion around competitive benchmarking in this…
Breaking through Barriers: Critical Success Factors for Launching Products with Breakthrough Therapy Designation
Posted by
Siddharth Agrawal , Andrew Therrien, PhD , Mark D. Bogost , Vivienne Ho, PhD on 7월 26, 20217/26/21
The FDA’s Breakthrough Therapy Designation (BTD) expedites patient access to innovative new treatments. While speeding up these processes can get new drugs to patients in need faster than they normally would through standard tracks, limited clinical…
BLOG: Pharmaceutical Value-based Contracts: Adherence and Supportive Contracts
Posted by
Dr. Richard Stefanacci on 7월 20, 20217/20/21
While there is a great deal of talk regarding value-based contracts in the life sciences industry, there are few successful examples. The difficulties in structuring these contracts begin with identification of outcomes that are directly and…
Navigating the Transition to Post-Approval Pharmacovigilance With EVERSANA and ArisGlobal
Partnering with a contract research organization (CRO) provider during clinical development fills an important role in the product life cycle, providing pharmaceutical companies with pharmacovigilance expertise and support during clinical trials. After product approvals, it can…